Publicaciones en colaboración con investigadores/as de The Bristol-Myers Squibb Children's Hospital (12)

2024

  1. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

    Nature Medicine, Vol. 30, Núm. 8, pp. 2199-2207

  2. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe

    Future Oncology, Vol. 20, Núm. 27, pp. 1993-2004

2023

  1. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

    Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321

  2. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

    Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128

2022

  1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414

  2. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

    Leukemia, Vol. 36, Núm. 5, pp. 1432-1435

  3. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

    Blood

  4. Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

    Journal of Clinical Oncology

2021

  1. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 13, pp. 1426-1436

2020

  1. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

    Blood, Vol. 135, Núm. 13, pp. 996-1007

2019

  1. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

    The Lancet Haematology, Vol. 6, Núm. 2, pp. e67-e78

2015

  1. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631